Prospective Multicenter Study of the Primary Obesity Surgery Endoluminal (POSE 2.0) Procedure for Treatment of Obesity
- PMID: 35533995
- DOI: 10.1016/j.cgh.2022.04.019
Prospective Multicenter Study of the Primary Obesity Surgery Endoluminal (POSE 2.0) Procedure for Treatment of Obesity
Abstract
Background & aims: The Primary Obesity Surgery Endoluminal (POSE) 2.0 procedure involves a novel pattern of full-thickness gastric body plications to shorten and narrow the stomach using durable suture anchor pairs. Our prospective, multicenter trial examined the safety, efficacy, durability, and physiologic effects of POSE 2.0 in adults with obesity.
Methods: Adults with obesity underwent POSE 2.0 at 3 centers. Primary outcomes were percent total body weight loss (%TBWL) and proportion of patients achieving >5% TBWL at 12 months. Secondary outcomes included change in obesity comorbidities, satiety, quality of life at 6 months, and durability of plications at 12 and 24 months. Subjects were followed for adverse events throughout the study duration.
Results: 44 patients (61% female; mean age, 45 ± 9.7 years; mean body mass index, 37 ± 2.1 kg/m2) were enrolled. This procedure used an average of 19 suture anchor pairs, with a mean duration of 37 ± 11 minutes, and was technically successful in all subjects. Mean %TBWL at 12 months was 15.7% ± 6.8%. At 12 months, %TBWL >5%, >10%, and >15% was achieved in 98%, 86%, and 58% of patients, respectively. Improvements in lipid profile, liver biochemistries, and hepatic steatosis were seen at 6 months. Improvements in hepatic steatosis persisted for 24 months in a subgroup of patients (P < .01). POSE 2.0 reduced maximum tolerated meal volume (P = .03) and was associated with increased fullness (P < .01) and improved eating behavior (P < .01) at 6 months. Impact of weight on quality-of-life questionnaire improved at 6 months (2.23 vs 1.23; P < .01). Repeat assessment at 24 months (n = 26) showed fully intact plications. No serious adverse events occurred.
Conclusion: POSE 2.0 is an effective and durable endoscopic bariatric therapy which may influence physiologic pathways impacting satiety. Larger comparative studies are needed to further elucidate these initial findings.
Clinicaltrials: gov Identifier: NCT03721731.
Keywords: Bariatric Endoscopy; Endoscopic Bariatric Therapy; Obesity; POSE2.0.
Copyright © 2023 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
MILEPOST Multicenter Randomized Controlled Trial: 12-Month Weight Loss and Satiety Outcomes After pose SM vs. Medical Therapy.Obes Surg. 2017 Feb;27(2):310-322. doi: 10.1007/s11695-016-2295-9. Obes Surg. 2017. PMID: 27468907 Clinical Trial.
-
Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice.Endoscopy. 2021 Nov;53(11):1169-1173. doi: 10.1055/a-1324-8498. Epub 2021 Jan 21. Endoscopy. 2021. PMID: 33246352
-
Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure.Endoscopy. 2023 Nov;55(11):1028-1034. doi: 10.1055/a-2117-6274. Epub 2023 Jun 26. Endoscopy. 2023. PMID: 37364600 Clinical Trial.
-
Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review and meta-analysis.Surg Endosc. 2022 Jan;36(1):252-266. doi: 10.1007/s00464-020-08267-z. Epub 2021 Feb 1. Surg Endosc. 2022. PMID: 33523277 Free PMC article.
-
Endoscopic Gastric Plication for Morbid Obesity: a Systematic Review and Meta-analysis of Published Data over Time.Obes Surg. 2019 Sep;29(9):3021-3029. doi: 10.1007/s11695-019-04010-3. Obes Surg. 2019. PMID: 31230201
Cited by
-
The Primary Obesity Surgery Endoluminal 2.0 Enfolding Technique (POSE 2.0et): Modification to Enhance Efficiency and Increase Restriction.Obes Surg. 2023 Jun;33(6):1953-1954. doi: 10.1007/s11695-023-06569-4. Epub 2023 Apr 17. Obes Surg. 2023. PMID: 37067685 No abstract available.
-
Advances in endobariatrics: past, present, and future.Gastroenterol Rep (Oxf). 2023 Jul 21;11:goad043. doi: 10.1093/gastro/goad043. eCollection 2023. Gastroenterol Rep (Oxf). 2023. PMID: 37483864 Free PMC article. Review.
-
A Comprehensive Review on Bariatric Endoscopy: Where We Are Now and Where We Are Going.Medicina (Kaunas). 2023 Mar 22;59(3):636. doi: 10.3390/medicina59030636. Medicina (Kaunas). 2023. PMID: 36984637 Free PMC article. Review.
-
Emerging Trends in Endoscopic Bariatric Therapies: Personalization Through Genomics and Synergistic Pharmacotherapy.J Clin Med. 2025 Jul 2;14(13):4681. doi: 10.3390/jcm14134681. J Clin Med. 2025. PMID: 40649055 Free PMC article. Review.
-
[POSE-2 for patients with obesity: a safe and effective treatment option].Chirurgie (Heidelb). 2024 Nov;95(11):934-936. doi: 10.1007/s00104-024-02186-8. Epub 2024 Sep 26. Chirurgie (Heidelb). 2024. PMID: 39325140 German. No abstract available.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical